Drug Approval | June 01, 2022
FDA approves Roche’s Evrysdi for use in babies under two months with SMA
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Auld is a seasoned Financial Executive with over 30 years of relevant experience
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The AI and technology upgrades allow doctors to choose their medical speciality and even spelling preferences to set their own speech model
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
Strategic partnership will develop a digital transformation roadmap and create opportunities for co-innovation in healthcare technologies
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
The new IGX-Track App adds seamless analysis of antibody panning campaigns to the IGX Platform
Subscribe To Our Newsletter & Stay Updated
